ETSI Telecomunicación, Universidad Politéctica de Madrid
Av. Complutense, 30, 28040, Madrid
It is estimated that around 9 million people are living with dementia in Europe. Dementia symptoms tend to get worse over time and gradually…
https://i0.wp.com/www.smart4md.eu/wp-content/uploads/2018/01/press-conference.png?fit=345%2C409409345smart4md_adminhttp://www.smart4md.eu/wp-content/uploads/2016/10/Logo-final-01-1-300x112.pngsmart4md_admin2018-01-12 11:07:402018-01-12 11:30:02ICT technologies empowering people with mild dementia and their carers 1st February, 8.00 – 14.00
The newly-launched feasibility study, involving 20 dyads of participants (20 people with dementia and 20 informal carers) - at least 75% of whom must agree that the system is easy to use - will pave the way for the main study kicking off in…
https://i2.wp.com/www.smart4md.eu/wp-content/uploads/2017/02/20161124_185352.jpg?fit=3264%2C183618363264smart4md_adminhttp://www.smart4md.eu/wp-content/uploads/2016/10/Logo-final-01-1-300x112.pngsmart4md_admin2017-06-28 12:49:522018-01-12 11:23:27SMART4MD project, intended to improve the quality of life of people with mild dementia, has entered its 'Feasibility Phase' with prototype testing in Spain and Sweden
BTH leder det EU-projekt som ska ta fram en applikation som ger människor med mild demens stöd och hjälp i det dagliga livet samt bättre kontroll över tillvaron.
– Projektet har två delar; dels att utveckla appens design så att den…
https://i0.wp.com/www.smart4md.eu/wp-content/uploads/2017/06/BTH-feasibility.jpg?fit=700%2C450450700smart4md_adminhttp://www.smart4md.eu/wp-content/uploads/2016/10/Logo-final-01-1-300x112.pngsmart4md_admin2017-06-27 15:38:322017-06-27 15:38:32SPECIALDESIGNAD APP SKA HJÄLPA MÄNNISKOR MED MILD DEMENS
November and December 2016 signalled 2 significant steps for DEX Innovation Centre in the development of the SMART4MD application for patients with mild dementia – a test of the developed clickable prototype among target groups and the ethical…
https://i2.wp.com/www.smart4md.eu/wp-content/uploads/2017/02/20161124_185352.jpg?fit=3264%2C183618363264smart4md_adminhttp://www.smart4md.eu/wp-content/uploads/2016/10/Logo-final-01-1-300x112.pngsmart4md_admin2016-12-21 16:41:172017-02-08 16:41:49A prototype of the SMART4MD application for patients with mild dementia and the ethical approval of its trial in the Czech Republic
Following a second round of focus groups conducted in Spain, Sweden, Czech Republic and Belgium, the findings were unanimous in validating the SMART4MD prototype as being highly usable by people living with mild dementia.
The research highlighted…
https://i2.wp.com/www.smart4md.eu/wp-content/uploads/2016/10/20161115_150920.jpg?fit=768%2C432432768smart4md_adminhttp://www.smart4md.eu/wp-content/uploads/2016/10/Logo-final-01-1-300x112.pngsmart4md_admin2016-10-24 18:56:262017-02-08 16:36:30Second round focus groups successful!
We want people to stay healthier for longer. SMART4MD is one way to empower people with mild dementia to take control of their health and, more importantly, their lives by retaining independence. We are delighted to be launching the pilot phase of our pan-European project, which heralds an important millstone for easily-accessible personalised healthcare.
Professor James Hampton-TillProject Co-Ordinator, Anglia Ruskin University
Several applications are already available for helping people with dementia in daily life activities. The SMART4MD study will however, be one of the few to measure the true value and impact of a mobile application via a large-scale clinical study in different EU countries. The involvement of the end-users (people with dementia, health professionals and carers) in the different development and testing phases of the application is a tremendous advantage. Cooperation with partners in the SMART4MD project will also boost the development of e-health applications for the elderly at our institution (research group ‘Active Ageing’ at University Colleges Leuven-Limburg, UCLL, Belgium).
Evi LemmensClinical Partner, University College Leuven-Limburg (UCLL), Belgium.
To date, there have been a number of interesting developments in applications to support people with cognitive decline. However, due to mostly small-scale trials, any impact has been difficult to establish, although the individuals often perceived them as beneficial. The much-needed SMART4MD study, with its randomised controlled design, provides an opportunity to demonstrate whether we can have a positive impact on clinical parameters and on people’s wellbeing.
Professor Johan Sanmartin BerglundClinical Lead, Bekinge Tekniska Hogskola, Sweden